Literature DB >> 26489379

Laser in infrapopliteal and popliteal stenosis 2 study (LIPS2): Long-term outcomes of laser-assisted balloon angioplasty versus balloon angioplasty for below knee peripheral arterial disease.

Chatchawan Piyaskulkaew1, Kesav Parvataneni1, Hussein Ballout1, Susan Szpunar1, Tarun Sharma1, Mohamed Almahmoud2, Thomas LaLonde1, Thomas Davis1, Rajendra H Mehta3, Hiroshi Yamasaki1.   

Abstract

BACKGROUND: Laser-assisted balloon angioplasty (LABA) has been shown to be more effective in achieving angiographic success for treatment for below knee peripheral artery disease (PAD) compared with balloon angioplasty alone(BA). However, long-term outcomes of LABA compared with BA for popliteal and infrapopliteal PAD are unknown.
METHODS: We evaluated data on 726 patients undergoing LABA (n = 395) and BA (n = 331) for popliteal and infrapopliteal PAD retrospectively at a single center (2007-2012). Outcomes included long-term ipsilateral major limb amputation, revascularization and mortality (median follow-up = 36 months).
RESULTS: Baseline features were similar in two groups with the exception of more TASC-D lesions (92.4 vs. 66.5%; P < 0.0001) and chronic total occlusions (86.4 vs. 49.5%; P < 0.0001) in LABA group. Angiographic success was higher in LABA compared with BA (97.7 vs. 89.2%; P < 0.0001). Ipsilateral major limb amputation (4.1 vs. 5.1%, P = 0.48) and repeat revascularization (25.1 vs. 23.3%, P = 0.47) were similar in LABA and BA patients despite unfavorable baseline angiographic characteristics in the former. Compared with BA, death was more frequently in LABA group (35.2 and 26.3%, P = 0.01), a reflection of higher comorbid conditions in this group (adjusted HR 1.05, 95% CI 0.79-1.39).
CONCLUSION: Despite worse baseline angiographic characteristics compared with BA, LABA was associated with higher angiographic success and similar ipsilateral major amputation, repeat revascularization, and long-term mortality. Future randomized clinical trial should evaluate the efficacy of LABA compared with BA (particularly drug-eluting) in improving limb salvage and reducing repeat revascularization in these high-risk PAD patients.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  balloon angioplasty; laser; peripheral arterial disease

Mesh:

Year:  2015        PMID: 26489379      PMCID: PMC5407062          DOI: 10.1002/ccd.26145

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  16 in total

1.  Race independently impacts outcome of infrapopliteal bypass for symptomatic arterial insufficiency.

Authors:  Vincent L Rowe; S Ram Kumar; Holly Glass; Douglas B Hood; Fred A Weaver
Journal:  Vasc Endovascular Surg       Date:  2007 Oct-Nov       Impact factor: 1.089

Review 2.  Critical limb ischemia.

Authors:  Sarah Elsayed; Leonardo C Clavijo
Journal:  Cardiol Clin       Date:  2015-02       Impact factor: 2.213

3.  Intermittent claudication. Incidence in the Framingham Study.

Authors:  W B Kannel; J J Skinner; M J Schwartz; D Shurtleff
Journal:  Circulation       Date:  1970-05       Impact factor: 29.690

4.  Laser in infra-popliteal and popliteal stenosis (LIPS): retrospective review of laser-assisted balloon angioplasty versus balloon angioplasty alone for below knee peripheral arterial disease.

Authors:  Tejwant Singh; Mihas Kodenchery; Surya Artham; Chatchawan Piyaskulkaew; Susanna Szpunar; Kesav Parvataneni; Hussein Ballout; Haroon Chugtai; Douglas Stewart; Thomas Lalonde; Hiroshi Yamasaki
Journal:  Cardiovasc Interv Ther       Date:  2013-10-24

5.  Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial.

Authors:  John R Laird; Thomas Zeller; Bruce H Gray; Dierk Scheinert; Mitar Vranic; Christopher Reiser; Giancarlo Biamino
Journal:  J Endovasc Ther       Date:  2006-02       Impact factor: 3.487

6.  Excimer laser assisted angioplasty for critical limb ischemia: results of the LACI Belgium Study.

Authors:  M Bosiers; P Peeters; F V Elst; F Vermassen; G Maleux; I Fourneau; H Massin
Journal:  Eur J Vasc Endovasc Surg       Date:  2005-06       Impact factor: 7.069

7.  Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss.

Authors:  Louis L Nguyen; Nathanael Hevelone; Selwyn O Rogers; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; Stuart Lipsitz; Michael S Conte
Journal:  Circulation       Date:  2008-12-22       Impact factor: 29.690

8.  Percutaneous transluminal laser angioplasty versus balloon dilation for treatment of popliteal artery occlusions.

Authors:  Hermann J Steinkamp; Jürgen Rademaker; Christian Wissgott; Dierk Scheinert; Michael Werk; Utz Settmacher; Roland Felix
Journal:  J Endovasc Ther       Date:  2002-12       Impact factor: 3.487

9.  Infrapopliteal angioplasty: long-term follow-up.

Authors:  K T Brown; E D Moore; G I Getrajdman; S Saddekni
Journal:  J Vasc Interv Radiol       Date:  1993 Jan-Feb       Impact factor: 3.464

10.  Clinical follow-up in endovascular treatment for TASC C-D lesions in femoro-popliteal segment.

Authors:  Martin Rabellino; Tobias Zander; Sebastian Baldi; Luis Garcia Nielsen; F Javier Aragon-Sanchez; Ignacio Zerolo; Rafael Llorens; Manuel Maynar
Journal:  Catheter Cardiovasc Interv       Date:  2009-04-01       Impact factor: 2.692

View more
  3 in total

1.  Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease.

Authors:  Yaowen Xiao; Zhong Chen; Yaoguo Yang; Lei Kou
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

2.  Management of Critical Limb Ischemia.

Authors:  Scott Kinlay
Journal:  Circ Cardiovasc Interv       Date:  2016-02       Impact factor: 6.546

3.  Cool Excimer Laser-Assisted Angioplasty vs. Percutaneous Transluminal Angioplasty for Infrapopliteal Arterial Occlusion: A Meta-Analysis and Systematic Review.

Authors:  Mi Zhou; Lixing Qi; Yongquan Gu
Journal:  Front Cardiovasc Med       Date:  2022-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.